抗B细胞成熟抗原BiTE分子AMG 420在复发难治多发性骨髓瘤中诱导缓解
AMG 420是一种靶向B细胞成熟抗原(BCMA)的BiTE分子,在42例复发难治多发性骨髓瘤患者中进行了首次人体研究。最大耐受剂量400 μg/d下,总缓解率为70%(7/10),其中5例达到微小残留病(MRD)阴性完全缓解。800 μg/d因3级细胞因子释放综合征和3级多神经病被认为不可耐受。
要点
- AMG 420在400 μg/d(最大耐受剂量)时总缓解率达70%(7/10)。
- 400 μg/d组中5例达MRD阴性完全缓解,1例部分缓解,1例非常好的部分缓解。
- 800 μg/d因3级细胞因子释放综合征和3级多神经病被认为不可耐受。
核心结论
- 在复发难治多发性骨髓瘤患者中,AMG 420在最大耐受剂量400 μg/d下总缓解率为70%,包括50%的MRD阴性完全缓解。
研究设计与样本
- 首次人体研究,纳入42例既往接受≥2线治疗且无髓外病变的复发难治多发性骨髓瘤患者。
- AMG 420以4周输注/6周为一周期,最多10个周期,剂量范围0.2-800 μg/d。
主要发现
- 42例患者中位年龄65岁,中位病程5.2年;缓解者中位暴露7个周期(范围1-10周期)。
- 总缓解率为31%(13/42);400 μg/d最大耐受剂量组缓解率为70%(7/10)。
- 400 μg/d组中5例达MRD阴性完全缓解,1例部分缓解,1例非常好的部分缓解;所有7例均在第一个周期内缓解,部分缓解持续>1年。
- 严重不良事件发生20例(48%),包括感染14例和多神经病2例;治疗相关严重不良事件包括2例3级多神经病和1例3级水肿。
- 800 μg/d因各1例3级细胞因子释放综合征和3级多神经病(均缓解)被认为不可耐受;无≥3级中枢神经系统毒性或抗AMG 420抗体。
关键数值与推荐
- MRD阴性定义为流式细胞术检测骨髓细胞中肿瘤细胞<1/10^4。
- 最大耐受剂量为400 μg/d;800 μg/d因3级细胞因子释放综合征和3级多神经病被认为不可耐受。
临床怎么用
- 对于复发难治多发性骨髓瘤,AMG 420在400 μg/d下显示出高缓解率及MRD阴性完全缓解,需关注感染和多神经病等不良事件。
局限性
- 首次人体研究,样本量较小(42例),最大耐受剂量组仅10例。
- 随访时间有限,部分缓解持续时间数据不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma. PATIENTS AND METHODS: In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week cycles). Patients had progression after ≥ 2 lines of prior therapy and no extramedullary disease. Minimal residual disease (MRD) response was defined as < 1 tumor cell/104 bone marrow cells by flow cytometry. RESULTS: Forty-two patients received AMG 420 at 0.2-800 μg/d. Median age was 65 years, and median disease duration was 5.2 years. Median exposure was 1 cycle (range, 1-10 cycles) and 7 cycles (range, 1-10 cycles) for responders. Patients discontinued for disease progression (n = 25), adverse events (AEs; n = 7), death (n = 4), completion of 10 cycles (n = 3), and consent withdrawal (n = 1). Two patients remain on treatment. There were 2 nontreatment-related deaths from AEs, influenza/aspergillosis and adenovirus-related hepatitis. Serious AEs (n = 20; 48%) included infections (n = 14) and polyneuropathy (n = 2); treatment-related serious AEs included 2 grade 3 polyneuropathies and 1 grade 3 edema. There were no grade ≥ 3 CNS toxicities or anti-AMG 420 antibodies. In this study, 800 μg/d was considered to not be tolerable because of 1 instance each of grade 3 cytokine release syndrome and grade 3 polyneuropathy, both of which resolved. The overall response rate was 31% (n = 13 of 42). At the maximum tolerated dose (MTD) of 400 μg/d, the response rate was 70% (n = 7 of 10). Of these, five patients experienced MRD-negative complete responses, and 1 had a partial response, and 1 had a very good partial response; all 7 patients responded during the first cycle, and some responses lasted > 1 year. CONCLUSION: In this study of AMG 420 in patients with relapsed/refractory multiple myeloma, the response rate was 70%, including 50% MRD-negative complete responses, at 400 μg/d, the MTD for this study.
引用
- Topp MS, Duell J, Zugmaier G, et al. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020. PMID: 31895611. doi:10.1200/JCO.19.02657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。